While the KIF11 inhibitor, Ispinesib, has already been tested in a phase I clinical trial in pediatric patients with recurrent/refractory tumors and demonstrated positive therapeutic response in three patients with disease stabilization in an additional patient, it has not been evaluated in GBM in clinical trials (111, 112). The gene discussed is KIF11; the disease is glioblastoma.